focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks lower as investors tread cautiously

Mon, 31st Mar 2014 16:58

- ECB under pressure to move on rates- Stocks erase gains but near three-week highs- Copper futures lower ahead of manufacturing PMIs- Small Russian troop pull backtechMARK 2,764.65 +0.09%FTSE 100 6,598.37 -0.26%FTSE 250 16,273.72 +0.57%UK stocks ended the day slightly lower as investors opted to bide their time ahead of Friday's US non-farm payrolls report and a barrage of data on the global manufacturing sector due out tomorrow.Worth noting, copper futures were changing hands at $303 per pound in early morning trading on COMEX, moving lower by approximately 0.51%. Acting as a backdrop, and linked to the above, a fair bit of market commentary could be seen referencing the risk of a steeper than expected slowdown in China's economy. Further weighing on sentiment was a weaker than expected reading on mortgage approvals for February. Data from the Bank of England revealed a decline to a monthly pace of 70,309, in comparison to the 76,753 seen in the month before and the 75,000 expected by the consensus. In parallel, European stocks were also getting weighed down by traders' cautiousness ahead of Thursday European Central Bank policy meeting. Reza Moghadam, Director of the IMF's European Department said today the central bank still has room to cut interest rates in face of the considerable downwards pressure on inflation.Figures released on Monday showed the annual rate of Eurozone consumer price inflation easing to a five-year low of 0.5% in March, down from 0.8% in February and below the 0.6% consensus forecast. The 'core' rate, which excludes volatile factors such as energy, food, alcohol and tobacco, fell to 0.8% from 1%, as expected.Ben May, European Economist at Capital Economics said that the slowdown in annual price rises was probably due to the timing of Easter, which fell in March last year. "But while we expect both headline and core inflation to pick up in April, underlying inflationary pressures will remain weak thanks to the large amount of spare economic capacity and the euro's strength," he said.May said it is "only a matter of time" before the European Central Bank (ECB) will decide that it needs to take "further policy action to prevent a worsening of the medium-term inflation outlook".Speaking in afternoon, Ukrainian Defence Ministry official Major-General Oleksandr Rozmaznin said the number of Russian troops deployed on the border with Ukraine is decreasing. He was unable to confirm numbers. "The number has definitely dropped and it (the situation) has calmed down. We won't rejoice and shout 'Hurray'. It doesn't matter how many of them there are, we just need to make sure our defences are strong," he said, according to Reuters.Babcock gains on nuclear contractEngineering group Babcock led gains after its joint venture, Cavendish Fluor Partnership, was selected as the preferred bidder for a UK government contract to manage the decommissioning of nuclear sites. According to the Nuclear Decommissioning Authority the 14-year contract is worth up to £7bn.Some miners also did well, including Anglo American and Rio Tinto, after Credit Suisse named them as its top picks in the metals and mining sector. Anglo was applauded for its restructuring potential, while the bank said that Rio's shareholder returns could be "larger and [...] sooner than any of its peer group".Analysts at Barclays raised their target price on ARM Holdings from 1125p to 1200p while reiterating their overweight recommendation.Insurance stocks such as Resolution and Aviva edged higher as share prices attempted to recover from the sell-off that ensued on Friday on the news of a regulatory investigation into the industry. The Financial Conduct Authority is set to outline its report today.Power systems giant Rolls-Royce gained after winning a $50m one-year contract to support the US Marines Corps fleet of KC-130J air-to-air refuelling tankers. GlaxoSmithKline declined after saying the third phase of its study of darpladib failed to meet its target for the prevention of stroke.Peel Hunt upgraded stock in African Barrick Gold to 'buy' from 'hold'.FTSE 100 - RisersBabcock International Group (BAB) 1,347.00p +4.26%Pearson (PSON) 1,063.00p +2.31%Mondi (MNDI) 1,049.00p +2.24%ARM Holdings (ARM) 998.00p +2.10%WPP (WPP) 1,237.00p +1.81%Rio Tinto (RIO) 3,337.50p +1.77%BAE Systems (BA.) 414.20p +1.67%Petrofac Ltd. (PFC) 1,438.00p +1.55%G4S (GFS) 241.50p +1.51%Aviva (AV.) 477.00p +1.45%FTSE 100 - FallersSSE (SSE) 1,469.00p -2.78%Shire Plc (SHP) 2,945.00p -2.52%St James's Place (STJ) 825.00p -2.25%Associated British Foods (ABF) 2,781.00p -1.73%GlaxoSmithKline (GSK) 1,591.50p -1.64%Sports Direct International (SPD) 852.00p -1.62%AstraZeneca (AZN) 3,876.50p -1.55%Tullow Oil (TLW) 748.50p -1.51%Next (NXT) 6,600.00p -1.49%Whitbread (WTB) 4,162.00p -1.44%FTSE 250 - RisersEvraz (EVR) 79.70p +10.62%African Barrick Gold (ABG) 263.50p +6.51%Xaar (XAR) 938.00p +5.99%CSR (CSR) 725.50p +4.54%Imagination Technologies Group (IMG) 203.20p +4.26%AL Noor Hospitals Group (ANH) 1,074.00p +3.67%Informa (INF) 528.50p +3.53%Alent (ALNT) 317.00p +3.49%Debenhams (DEB) 79.95p +3.09%Daejan Holdings (DJAN) 4,890.00p +3.06%FTSE 250 - FallersFisher (James) & Sons (FSJ) 1,463.00p -2.27%esure Group (ESUR) 279.70p -2.24%Entertainment One Limited (ETO) 330.00p -2.22%NMC Health (NMC) 504.50p -2.04%Howden Joinery Group (HWDN) 372.10p -1.85%Carphone Warehouse Group (CPW) 324.90p -1.84%Cairn Energy (CNE) 166.90p -1.71%EnQuest (ENQ) 124.00p -1.67%Direct Line Insurance Group (DLG) 237.50p -1.66%Soco International (SIA) 396.00p -1.49%AB
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.